Repligen Corporation (NASDAQ: RGEN) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Repligen Corporation and Rockwell Medical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Repligen Corporation $113.32 million 12.63 $29.54 million $0.51 75.14
Rockwell Medical $54.04 million 8.20 -$21.07 million ($0.42) -20.38

Repligen Corporation has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

97.9% of Repligen Corporation shares are owned by institutional investors. Comparatively, 21.4% of Rockwell Medical shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by company insiders. Comparatively, 15.9% of Rockwell Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Repligen Corporation and Rockwell Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen Corporation 0 2 2 0 2.50
Rockwell Medical 1 0 1 1 2.67

Repligen Corporation presently has a consensus price target of $44.25, indicating a potential upside of 15.47%. Rockwell Medical has a consensus price target of $9.33, indicating a potential upside of 9.03%. Given Repligen Corporation’s higher probable upside, equities research analysts clearly believe Repligen Corporation is more favorable than Rockwell Medical.

Volatility & Risk

Repligen Corporation has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Profitability

This table compares Repligen Corporation and Rockwell Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repligen Corporation 15.61% 9.90% 5.93%
Rockwell Medical -39.68% -42.22% -27.15%

Summary

Repligen Corporation beats Rockwell Medical on 10 of the 14 factors compared between the two stocks.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Rockwell Medical Company Profile

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.